Abstract 1165
Background
Although several studies report the clinical characteristics of bacteremia by Aeromonas species, there is a lack of studies about the bacteremia course in hematologic malignancies. Our aim was to determine the risk factors for bacteremia-associated mortality by Aeromonas sobria in patients with hematological malignancies.
Methods
We performed a retrospective cohort study, by reviewing 37 medical records of patients treated at the “Instituto Nacional de Enfermedades Neoplasicas-Peru”, in the period of 2000-2017. We considered a bacteremia-related death if it occurred within the first 7 days of A. sobria isolation, or during the acute course of sepsis. Risk factors were assessed by the Multivariate Cox regression analysis at 30 days after the patient’s admission.
Results
The median age was 24y (2-74y), six patients (16.2%) had ≥65y, and 54.1% were male. The most common diagnosis was lymphoid leukemia (51.4%), followed by myeloid leukemia (27%), high-grade lymphoma (18.9%), and multiple myeloma (2.7%); and 37.8% had community-acquired bacteremia. The gastrointestinal system was the most common primary source of infection (62.2%), followed by the osteoarticular system (18.9%). The mortality rate was 27%, and 11 cases (29.7%) presented septic shock. Furthermore, antibiotic use was as follow, meropenem (64.9%), ceftazidime (37.8%), and amikacin (29.7%). Multivariate Cox regression identified age ≥65, shock, and no disease remission as independent risk factors for mortality (Table). Risk factors for Bacteremia-Associated Mortality of Aeromona sobria.Table: 1093P
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
HR | 95% CI | P-value | HR | 95% CI | P-value | |
Age ≥65 | 5.48 | 1.5-19.7 | 0.01 | 8.13 | 1.7-39.4 | 0.009 |
Community-acquire bacteremia | 9.73 | 2.1– 46.1 | 0.004 | - | - | - |
Shock | 13.21 | 2.8–63.0 | 0.001 | 7.06 | 1.5-34.4 | 0.016 |
Non-disease remission | 14.31 | 1.8–113.3 | 0.012 | 10.46 | 1.2-89.8 | 0.024 |
Conclusions
Patients with hematological malignancy infected by A. sobria that either is ≥ 65-years-old does not have a disease remission or develop shock, the risk of dying increases. The physicians can use our results to guide the prognosis of patients infected by this bacteria.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract